What Is the Benzodiazepine Information Coalition, and How Does It Help During a Taper?

What is the Benzodiazepine Information Coalition?

The Benzodiazepine Information Coalition (BIC) is a nonprofit organization formed by patients and medical professionals. Its mission is education about the adverse effects that benzodiazepines can cause, even when they are taken as prescribed. Its website is benzoinfo.com. Its material also covers the z-drugs, the sleep medications such as zolpidem (Ambien) that act on the same receptors.

People shorten the name in different ways. A search for the “Benzo Info Coalition” or the “Benzo Coalition” is usually a search for this organization.

The person looking for it is rarely someone who misused a medication. More often, it is a patient who took alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), or diazepam (Valium) exactly as directed, sometimes for years, and then became ill when the dose was lowered or missed. Often, nobody had mentioned that this could happen.

So, what does the Coalition stand for, and how does a patient put it to use during a taper?

What does the Coalition advocate?

Two things stand out. The first is informed consent, which means that a person offered a benzodiazepine hears about the risks before the first prescription is written. The second is safe, gradual tapering for the patient who decides to come off.

The phrase “taken as prescribed” is the center of it. The harm the Coalition describes does not require misuse. It can follow an ordinary prescription, filled on time and taken as the label says.

It also helps to know what the Coalition is not. It is not a peer forum, and it is not a medical practice. As an organization, it does not examine patients, write prescriptions, or manage anyone’s taper.

Does the Coalition want benzodiazepines banned?

No. BIC does not seek a ban on these medications, which surprises people who expect an advocacy group to oppose the medication itself.

The argument is about information. Whether to start a benzodiazepine, stay on one, or come off is a decision for the patient, and a decision is only as good as the information behind it.

There is a practical reason as well. A person who is already physically dependent is harmed by losing a medication suddenly. In fact, a slow taper depends on a steady prescription that comes down a little at a time.

Patients noticed the problem before medicine did.

Professor C. Heather Ashton ran a benzodiazepine withdrawal clinic for twelve years, from 1982 to 1994. In the first chapter of the Ashton Manual, she wrote that much of what she knew about the subject was taught to her by the people who came to that clinic. She also wrote that “the patients themselves, and not the medical profession, were the first to realise that long-term use of benzodiazepines can cause problems.”

In the same chapter, she described people who became dependent on prescribed, therapeutic doses taken for months or years. These were not people who went looking for a drug. They were people who followed a doctor’s instructions.

The official warning arrived much later. In 2020, the United States Food and Drug Administration (FDA) required an update to the boxed warning for all benzodiazepines. The agency stated that physical dependence can occur when these medications are taken steadily for several days to weeks, even as prescribed.

The agency also acknowledged that the prescribing information in use at the time did not give adequate warnings about these risks. Unfortunately, a warning on a label does not reach every patient.

Patients often describe the same history, which is a prescription, a reassurance that the medication was safe, and no mention of dependence. An organization formed by patients and medical professionals exists to say what was left out.

Is a patient who cannot stop a prescribed benzodiazepine addicted?

In nearly all cases, no. The body has adapted to a medication taken every day, and it reacts when the dose falls. That is physical dependence. Physical dependence is not addiction.

The words matter because the care follows the word. A patient who is called addicted tends to be sent toward addiction programs with short, fixed timelines. A nervous system that adapted over years does not readjust in a few weeks, and a fast withdrawal raises the risk of severe symptoms that linger.

The Coalition’s focus on benzodiazepines taken as prescribed starts from the same place. Its subject is the patient who did what the prescription said. There is more in the article on why the addiction label is wrong for a person with benzodiazepine dependence.

What is the connection between the Coalition and this practice?

Dr. Mark Leeds, the physician behind this website, serves on the Coalition’s medical advisory board. He is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida. The Coalition argues for informed consent and safe tapering in general terms, and his practice applies those principles to one patient at a time.

First, a patient with physical dependence has a medical condition, and the care should be medical. That means a gradual taper. It does not mean a program designed for a different problem.

Second, the taper is slow, and the patient directs it. In Chapter II of the Ashton Manual, Professor Ashton wrote that the patient should be in control of the schedule and should not let a doctor impose a deadline. She noted that many people have taken a year or more. The FDA’s 2020 update makes a matching point, that no standard tapering schedule is suitable for all patients.

In practice, that means a small reduction, and then a wait while the nervous system settles. The reductions get smaller as the dose gets lower, which is the hyperbolic pattern described in the Maudsley Deprescribing Guidelines. Where it helps, the plan includes a crossover taper to diazepam, as the Ashton Manual describes. The question of who should set the pace of a benzodiazepine taper has an article of its own.

Third, informed consent is more than a signature. The risks come first, including physical dependence, tolerance, and withdrawal. The patient hears the alternatives, including no medication at all, has an exit plan from the first day, and keeps the right to decline at any point.

How does a patient use the Coalition alongside a prescriber-led taper?

Educational material is like a road atlas. It shows the whole route, yet it cannot see the weather on the day of the drive. The prescriber and the patient watch the weather together, one reduction at a time.

So, the Coalition’s website is for reading. It helps at the beginning, when a patient needs to know that the symptoms have a name and a cause. It helps again before an appointment, when reading turns into questions. Is the plan gradual, who sets the pace, and what happens if a reduction proves too large?

It also helps at home. Relatives who doubt that a prescribed medication could cause all of this will sometimes believe an outside organization, or the FDA’s own warning, before they believe the patient. Peer support, a steady routine, and an understanding family can make the months easier, though none of these treats withdrawal and what helps varies from person to person. The article on support groups during a benzodiazepine taper covers that ground.

What the Coalition cannot do is manage a dose. It does not know a patient’s medication, history, or other prescriptions, and no website does. Any change to a dose belongs in a conversation with the prescriber first.

Stopping without a plan is the one thing to avoid. The FDA warns that stopping a benzodiazepine abruptly, or reducing the dose too quickly, can cause withdrawal reactions, including seizures, that can be life-threatening. A seizure, or any other medical emergency, is a reason to call 911 right away.

What if the prescriber does not recognize benzodiazepine dependence?

Professor Ashton was plain that a taper needs the prescriber’s agreement and cooperation, since the prescriber writes the prescriptions. While some doctors welcome a patient who arrives with the Manual and the FDA warning in hand, others do not.

In that case, the next step is finding care from a doctor who recognizes benzodiazepine dependence. It is never to taper in secret, and it is never to stop abruptly.

Reading about a taper is not the same as having one supervised.

Patients were the first to see this problem, and for a long time they were not believed. Fortunately, they no longer have to rely on their own word. The warning is on the label, the Ashton Manual is free to read online, and an organization exists to keep that information in public view.

Yet, information alone does not lower a dose. That takes a prescriber, a plan built for one person, and time. In most cases, with a slow taper, the nervous system does readjust.

Dr. Leeds’ practice provides medically supervised benzodiazepine and z-drug tapering for patients in Florida. Each plan is built for one patient, the pace is set together with that patient, and no reduction happens on a deadline. Contact the office to ask about a gradual, medically supervised taper in Florida.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.